Letter

Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply

Rob J Vandebriel1*, Hilda JI De Jong123, Eric R Gremmer1, Olaf H Klungel3, Jan-Willem Cohen Tervaert4, Wout Slob5, Jan W Van Der Laan6 and Henk Van Loveren12

Author Affiliations

1 Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, the Netherlands

2 Department of Toxicogenomics, Maastricht University, Universiteitssingel 50, PO Box 616, 6200 MD Maastricht, the Netherlands

3 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, PO Box 80 082, 3508 TB Utrecht, the Netherlands

4 Department of Internal Medicine, Division of Clinical and Experimental Immunology, University Hospital Maastricht, Universiteitssingel 50, PO Box 616, 6200 MD Maastricht, the Netherlands

5 Centre for Substances and Integrated Risk Assessment, National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, the Netherlands

6 Section on Pharmacology, Toxicology and Biotechnology (FTBB), Medicines Evaluation Board, Graadt van Roggenweg 500, PO Box 8275, 3503 RG Utrecht, the Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2013, 15:403  doi:10.1186/ar4170


See related research by Vandebriel et al., http://arthritis-research.com/content/14/2/R90, and related letter by Mathieu et al., http://arthritis-research.com/content/15/2/402

Published: 8 March 2013

First paragraph (this article has no abstract)

We thank Mathieu and colleagues for their interest in our recent publication [1] and for reporting their very interesting experiments showing that intraperitoneal but not subcutaneous simvastatin inhibits arthritis progression in the mouse collagen-induced arthritis (CIA) model [2]. These results are in line with those of Palmer and colleagues, who showed that intraperitoneal but not oral simvastatin administration inhibited pre-existing CIA [3].